Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer
2.
Obesity linked to subsequent neoplasms in childhood cancer survivors
3.
For older patients with Hodgkin lymphoma, novel regimens produce high response rates.
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.
1.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
2.
Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights
3.
Lymphomatoid Papulosis: What You Need to Know
4.
An Introduction To The CA 15-3 Tumor Marker Test For Cancer Patients
5.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge